US-based biotechnology company Morphic Therapeutic closed a $51.5m series A round yesterday co-led by SR One and Pfizer Venture Investments, the respective corporate venturing units of pharmaceutical firms GlaxoSmithKline and Pfizer. AbbVie Ventures, the investment arm of biopharmaceutical firm AbbVie; ShangPharma Investment Group, the corporate venturing vehicle of pharmaceutical holding firm ShangPharma; and chemical simulation… Continue reading Morphic transforms interest into series A cash
Month: July 2016
Citi helps Cylance close $100m series D opportunity
Cybersecurity software developer Cylance has added Citi Ventures to its list of shareholders, achieving the final close of its $100m series D round.
Zenefits shreds series C valuation to quell investor discontent
The HR software provider has raised the stake issued in May 2015 through the $500m Comcast-backed round from 11% to 25% in the wake of a regulatory scandal.